Pseudomyxoma peritonei natural history, complications and prognosis: Difference between revisions
Nima Nasiri (talk | contribs) |
|||
| Line 6: | Line 6: | ||
==Natural History== | ==Natural History== | ||
If left untreated, patients with pseudomyxoma peritonei may progress to develop abdominal or pelvic pain, [[bloating]], [[abdominal distension]], [[weight change]], and [[infertility]]. | If left untreated, patients with pseudomyxoma peritonei may progress to develop abdominal or pelvic pain, [[bloating]], [[abdominal distension]], [[weight change]], and [[infertility]]. | ||
*PMP has generally been considered benign; however its behaviour suggests that it should, at best, be considered a borderline malignancy with disease progression over time, to massive abdominal distension and nutritional compromise in most cases. The long term survival in most patients remains poor with reported 5 and 10 year survival rates of 50% and 10%-30%, respectively | |||
==Prognosis== | ==Prognosis== | ||
*Although pseudomyxoma peritonei as a neoplastic disease runs a chronic, indolent course with late invasion and only rare metastasis outside the peritoneum, it is a serious, recurrent condition with life-threatening complications.<ref name="AminiMasoumi-Moghaddam2014">{{cite journal|last1=Amini|first1=Afshin|last2=Masoumi-Moghaddam|first2=Samar|last3=Ehteda|first3=Anahid|last4=Morris|first4=David|title=Secreted mucins in pseudomyxoma peritonei: pathophysiological significance and potential therapeutic prospects|journal=Orphanet Journal of Rare Diseases|volume=9|issue=1|year=2014|pages=71|issn=1750-1172|doi=10.1186/1750-1172-9-71}}</ref> | *Although pseudomyxoma peritonei as a neoplastic disease runs a chronic, indolent course with late invasion and only rare metastasis outside the peritoneum, it is a serious, recurrent condition with life-threatening complications.<ref name="AminiMasoumi-Moghaddam2014">{{cite journal|last1=Amini|first1=Afshin|last2=Masoumi-Moghaddam|first2=Samar|last3=Ehteda|first3=Anahid|last4=Morris|first4=David|title=Secreted mucins in pseudomyxoma peritonei: pathophysiological significance and potential therapeutic prospects|journal=Orphanet Journal of Rare Diseases|volume=9|issue=1|year=2014|pages=71|issn=1750-1172|doi=10.1186/1750-1172-9-71}}</ref> | ||
Revision as of 15:20, 7 January 2019
|
Pseudomyxoma peritonei Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Pseudomyxoma peritonei natural history, complications and prognosis On the Web |
|
American Roentgen Ray Society Images of Pseudomyxoma peritonei natural history, complications and prognosis |
|
FDA on Pseudomyxoma peritonei natural history, complications and prognosis |
|
CDC on Pseudomyxoma peritonei natural history, complications and prognosis |
|
Pseudomyxoma peritonei natural history, complications and prognosis in the news |
|
Blogs on Pseudomyxoma peritonei natural history, complications and prognosis |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Parminder Dhingra, M.D. [2]
Overview
If left untreated, patients with pseudomyxoma peritonei may progress to develop abdominal or pelvic pain, bloating, abdominal distension, weight change, and infertility. Prognosis is generally good and the 10-year survival rate of patients with pseudomyxoma peritonei is approximately 63%.
Natural History
If left untreated, patients with pseudomyxoma peritonei may progress to develop abdominal or pelvic pain, bloating, abdominal distension, weight change, and infertility.
- PMP has generally been considered benign; however its behaviour suggests that it should, at best, be considered a borderline malignancy with disease progression over time, to massive abdominal distension and nutritional compromise in most cases. The long term survival in most patients remains poor with reported 5 and 10 year survival rates of 50% and 10%-30%, respectively
Prognosis
- Although pseudomyxoma peritonei as a neoplastic disease runs a chronic, indolent course with late invasion and only rare metastasis outside the peritoneum, it is a serious, recurrent condition with life-threatening complications.[1]
- Biological features of the tumor and access to the current standard of care at specialized oncology centers with a peritoneal surface malignancy program comprise the most important prognostic determinants of pseudomyxoma peritonei.
- Through a retrospective, multi-institutional study on 2298 patients treated at 16 specialized centers affiliated with the Peritoneal Surface Oncology Group International, Chua et al. reported a median survival rate of 196 months (16.3 years) and a median progression-free survival rate of 98 months (8.2 years) as well as 10- and 15-year survival rates of 63% and 59%, respectively.
References
- ↑ Amini, Afshin; Masoumi-Moghaddam, Samar; Ehteda, Anahid; Morris, David (2014). "Secreted mucins in pseudomyxoma peritonei: pathophysiological significance and potential therapeutic prospects". Orphanet Journal of Rare Diseases. 9 (1): 71. doi:10.1186/1750-1172-9-71. ISSN 1750-1172.